DOI QR코드

DOI QR Code

Prognostic value of FDG PET/CT during radiotherapy in head and neck cancer patients

  • Kim, Suzy (Department of Radiation Oncology, Seoul National University Boramae Medical Center) ;
  • Oh, Sowon (Department of Nuclear Medicine, Seoul National University Boramae Medical Center) ;
  • Kim, Jin Soo (Department of Internal Medicine, Seoul National University Boramae Medical Center) ;
  • Kim, Yu Kyeong (Department of Nuclear Medicine, Seoul National University Boramae Medical Center) ;
  • Kim, Kwang Hyun (Department of Otolaryngology, Seoul National University Boramae Medical Center) ;
  • Oh, Do Hoon (Department of Radiation Oncology, Chung-Ang University Hostpial) ;
  • Lee, Dong-Han (Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital) ;
  • Jeong, Woo-Jin (Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital) ;
  • Jung, Young Ho (Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital)
  • Received : 2017.12.22
  • Accepted : 2018.03.14
  • Published : 2018.06.30

Abstract

Purpose: To evaluate the prognostic value of $^{18}F$-fluorodeoxyglucose positron-emission tomography (FDG PET) with computed tomography (CT) before and during radiotherapy (RT) in patients with head and neck cancer. Methods: Twenty patients with primary head and neck squamous cell carcinoma were enrolled in this study, of whom 6 had oropharyngeal cancer, 10 had hypopharyngeal cancer, and 4 had laryngeal cancer. Fifteen patients received concurrent cisplatin and 2 received concurrent cetuximab chemotherapy. FDG PET/CT was performed before RT and in the 4th week of RT. The parameters of maximum standardized uptake value, metabolic tumor volume, and total lesion glycolysis (TLG) of the primary tumor were measured, and the prognostic significance of each was analyzed with the Cox proportional hazards model. Results: Higher TLG (>19.0) on FDG PET/CT during RT was a poor prognostic factor for overall survival (OS) (p = 0.001) and progression-free survival (PFS) (p = 0.007). In the multivariate analysis, TLG during RT as a continuous variable was significantly associated with OS and PFS rate (p = 0.023 and p = 0.016, respectively). Tumor response worse than partial remission at 1 month after RT was another independent prognostic factor for PFS (p = 0.024). Conclusions: Higher TLG of the primary tumor on FDG PET/CT during RT was a poor prognostic factor for OS and PFS in patients with head and neck cancer.

Keywords

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. https://doi.org/10.3322/caac.21332
  2. Bourhis J, Le Maitre A, Baujat B, et al. Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol 2007;19:188-94. https://doi.org/10.1097/CCO.0b013e3280f01010
  3. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78. https://doi.org/10.1056/NEJMoa053422
  4. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8. https://doi.org/10.1016/S1470-2045(09)70311-0
  5. Givens DJ, Karnell LH, Gupta AK, et al. Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2009;135:1209-17. https://doi.org/10.1001/archoto.2009.174
  6. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004;22:2856-64. https://doi.org/10.1200/JCO.2004.12.012
  7. Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group phase II trial 99-14. J Clin Oncol 2005;23:3008-15. https://doi.org/10.1200/JCO.2005.12.060
  8. Syed R, Bomanji JB, Nagabhushan N, et al. Impact of combined (18)F-FDG PET/CT in head and neck tumours. Br J Cancer 2005;92:1046-50. https://doi.org/10.1038/sj.bjc.6602464
  9. Baek CH, Chung MK, Son YI, et al. Tumor volume assessment by 18F-FDG PET/CT in patients with oral cavity cancer with dental artifacts on CT or MR images. J Nucl Med 2008;49:1422-8. https://doi.org/10.2967/jnumed.108.051649
  10. Abgral R, Keromnes N, Robin P, et al. Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2014;41:659-67. https://doi.org/10.1007/s00259-013-2618-1
  11. Kim JW, Oh JS, Roh JL, et al. Prognostic significance of standardized uptake value and metabolic tumour volume on 18F-FDG PET/CT in oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2015;42:1353-61. https://doi.org/10.1007/s00259-015-3051-4
  12. Abgral R, Le Roux PY, Keromnes N, et al. Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2012;39:1839-47. https://doi.org/10.1007/s00259-012-2213-x
  13. Yoon DH, Cho Y, Kim SY, et al. Usefulness of interim FDGPET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2011;81:118-25. https://doi.org/10.1016/j.ijrobp.2010.04.034
  14. Kim S, Oh SW, Kim JS, Kim KH, Kim YK. Prediction of response by FDG PET early during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. Radiat Oncol J 2014;32:231-7. https://doi.org/10.3857/roj.2014.32.4.231
  15. Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003;57:853-63. https://doi.org/10.1016/S0360-3016(03)00346-8
  16. Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in earlystage non-small cell lung cancer after surgical resection. Ann Surg 2013;257:364-70. https://doi.org/10.1097/SLA.0b013e318262a6ec
  17. Pak K, Cheon GJ, Nam HY, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med 2014;55:884-90. https://doi.org/10.2967/jnumed.113.133801
  18. Moon SH, Choi JY, Lee HJ, et al. Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck 2013;35:15-22. https://doi.org/10.1002/hed.22904
  19. Pollom EL, Song J, Durkee BY, et al. Prognostic value of midtreatment FDG-PET in oropharyngeal cancer. Head Neck 2016;38:1472-8. https://doi.org/10.1002/hed.24454
  20. Min M, Lin P, Lee MT, et al. Prognostic role of metabolic parameters of (18)F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2015;42:1984-94. https://doi.org/10.1007/s00259-015-3104-8
  21. Kitao T, Hirata K, Shima K, et al. Reproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer. BMC Cancer 2016;16:576. https://doi.org/10.1186/s12885-016-2624-3
  22. Toda K, Torihara A, Nakagawa M, et al. Time dependency of volume-based metabolic parameters obtained by dual-timepoint TOF-PET/CT for head and neck squamous cell cancer. Int J Radiat Oncol Biol Phys 2017;99(2S):E377-E378.
  23. Chen SW, Hsieh TC, Yen KY, et al. Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer. Laryngoscope 2014;124:2732-8. https://doi.org/10.1002/lary.24826
  24. Hoang JK, Das SK, Choudhury KR, Yoo DS, Brizel DM. Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change. AJNR Am J Neuroradiol 2013;34:1428-33. https://doi.org/10.3174/ajnr.A3412
  25. Lin P, Min M, Lee M, et al. Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers. Eur J Nucl Med Mol Imaging 2017;44:801-11. https://doi.org/10.1007/s00259-016-3584-1
  26. Garibaldi C, Ronchi S, Cremonesi M, et al. Interim (18)F-FDG PET/CT during chemoradiation therapy in the management of head and neck cancer patients: a systematic review. Int J Radiat Oncol Biol Phys 2017;98:555-73. https://doi.org/10.1016/j.ijrobp.2017.02.217

Cited by

  1. The Prognostic Role of Maximum Standardized Uptake Value of 18 F-FlouroDeoxy Glucose Positron Emission Tomography-Computed Tomography in Head and Neck Cancer Patients Undergoing Chemoradiotherapy vol.9, pp.2, 2018, https://doi.org/10.4103/jispcd.jispcd_409_18
  2. Metabolic tumor volume and total lesion glycolysis as prognostic factors in head and neck cancer: Systematic review and meta‐analysis vol.42, pp.12, 2020, https://doi.org/10.1002/hed.26461
  3. Recent advances of PET imaging in clinical radiation oncology vol.15, pp.1, 2020, https://doi.org/10.1186/s13014-020-01519-1
  4. Early Metabolic Response Assessed Using 18F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer vol.53, pp.3, 2018, https://doi.org/10.4143/crt.2020.1251
  5. Correlations between DW‐MRI and 18 F‐FDG PET / CT parameters in head and neck squamous cell carcinoma following definitive chemo‐radi vol.4, pp.4, 2018, https://doi.org/10.1002/cnr2.1360
  6. Analysis of PET parameters as prognosticators of survival and tumor extent in Oropharyngeal Cancer treated with surgery and postoperative radiotherapy vol.21, pp.1, 2018, https://doi.org/10.1186/s12885-021-08035-9